← Back to Search

Arm I (Transfusion for Hgb less than 7 g/dL) for Pancreatic Cancer

Phase < 1

Recruiting

Led By Edward Livingston, MD

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male or female >= 18 years of age at Visit 1

CT evidence of a mass in the pancreas consistent with cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing whether giving more red blood cell transfusions to patients undergoing pancreatic cancer surgery can improve their quality of life. Pancreatic cancer surgery can cause a lot of blood loss, which can

Who is the study for?

This trial is for adults over 18 with CT evidence of pancreatic cancer and a tissue diagnosis confirming the disease. Candidates should be evaluated as suitable for pancreatic surgery and must provide written consent to participate.Check my eligibility

What is being tested?

The study tests two different red blood cell transfusion strategies (using lower or higher hemoglobin levels as triggers) in patients undergoing pancreatectomy for pancreatic cancer, aiming to see which improves quality of life.See study design

What are the potential side effects?

Possible side effects from receiving blood transfusions include allergic reactions, fever, iron overload, lung injury, and infections. The risks vary depending on individual health conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My CT scan shows a mass in the pancreas that may be cancer.

Select...

My doctors think surgery to remove my pancreas is possible.

Select...

My cancer was confirmed by a tissue test before or after surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of Protocol adherence

Secondary outcome measures

Health related quality of life

Incidence of significant individual adverse events

Length of stay in hospital and intensive care unit (ICU)

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm II (Transfusion for Hgb less than 9 g/dL)Experimental Treatment6 Interventions

Patients undergo red blood cell transfusion if Hgb is less than 9 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.

Group II: Arm I (Transfusion for Hgb less than 7 g/dL)Experimental Treatment6 Interventions

Patients undergo red blood cell transfusion if Hgb is less than 7 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Computed Tomography

2017

Completed Phase 2

~2720

Biospecimen Collection

2004

Completed Phase 2

~1700

Pancreatectomy

2012

Completed Phase 2

~160

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

361 Previous Clinical Trials

27,802 Total Patients Enrolled

Edward Livingston, MDPrincipal InvestigatorUniversity of California at Los Angeles

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of participants involved in this clinical investigation?

"Indeed, the information available on clinicaltrials.gov confirms that this trial is actively seeking eligible candidates. The trial was initially posted on August 10th, 2023 and last updated on January 17th, 2024. This study aims to enroll a total of 10 participants from one designated location."

Answered by AI

Are patients currently able to participate in this ongoing trial?

"Indeed, according to the details found on clinicaltrials.gov, this trial is currently actively seeking eligible participants. The initial posting of the study was made on August 10th, 2023, and it underwent its most recent update on January 17th, 2024."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

2023. "Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05841706.